Worldwide there are currently over 1200 research studies being performed on the topic of COVID-19. Many of these involve children and adults over age 65 years. There are also numerous studies testing investigational vaccines on healthy volunteers. No research team is exempt from the pressures and speed at which COVID-19 research is occurring. And this can increase the risk of honest error as well as misconduct. To date, 33 papers have been identified as unsuitable for public use and either retracted, withdrawn, or noted with concern. Asia is the source of most of these manuscripts (n=19; 57.6%) with China the largest Asian subgroup (n=11; 57.9%). This paper explores these findings and offers guidance for responsible research practice during pandemics.
- research ethics
- public health ethics
This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
As of 7 May 2020, the international clinical trial registry site, ClinicalTrials.gov, reported 1221 registered studies focused on COVID-19 (table 1).1 Of these, 214 (17.5%) include children as research participants, and 1155 (94.6%) include adults age 65 years and older. Healthy volunteers are the cohort for 243 (19.9%) studies, and of these, 13 (5.4%) are vaccine clinical trials. Most studies are being performed in Europe and North America where research ethics regulations are robust; however, no location is exempt from the pressures and speed at which COVID-19 research is occurring. This can increase the risk of honest error as well as misconduct.1
According to WHO, the first cases of COVID-19 occurred in China in December 2019.2 Other sources indicate the first case could have been in November 2019.3 As the virus rapidly spread from an epidemic to a pandemic, researchers worldwide began the search for treatments and vaccines. Journals have been flooded with manuscript submissions4 and more journals are providing open access,5 allowing the research to be readily viewed by clinicians who can potentially then use the research for clinical decision-making.
Problematic pandemic research publications
As of 31 July 2020, 19 published articles and 14 preprints about COVID-19 have been retracted, withdrawn, or an expression of concern has been issued (tables 2 and 3).2 The source of most of these incidents is Asia (n=19; 57.6%), with China the largest Asian subgroup (n=11; 57.9%). For three papers, the reason for the removal is unknown; however, for the others, a range of problems exist, including data falsification, methodological concerns, and concerns about interpretation of data and conclusions, as well as authorship and research participant privacy issues (table 4). To date, there have been no identified reports of plagiarism or data fabrication. Another paper, a preprint from the USA about COVID-19 antibody seroprevalence, has come under scrutiny for an undisclosed conflict of interest, but no official findings have been issued.6 7
Complications of publishing problematic research
There has been a surge of almost 4000 papers related to COVID-19 placed on preprint servers recently.8 These platforms provide a lower level of quality checks compared with a full peer review process by journals. Accordingly, preprint platforms do routinely advise their readers not to use their content for clinical decision-making, but the latter cannot be ruled out, especially in the situation of a pandemic with high rates of morbidity and mortality. Patient harm that is significant, permanent and irreversible could result from using faulty research results from preprints as well as published papers. Published papers are interpreted as vetted via peer review, with an inference of quality and accuracy and clinicians are likely to refer to them for guidance.
The act of retraction follows a thorough investigation and concern about a paper’s integrity (eg, methods, data analysis, data interpretation, data reporting). While not as severe as a retraction, an expression of concern announces to potential readers that a paper should be read with caution due to potential integrity issues. Both retraction and expression of concern are markers of integrity issues that reflect on the authors and their institutional affiliation. Retracted research can have direct funding costs due to waste and payback requirements, as well as decreased future funding.9 Sometimes, the integrity of the journal can also be implicated if the matter is associated with a less than robust peer review process or a deficient conflict of interest assessment.
Even if only one author’s behaviour is confirmed as the source of an article’s retraction or concern, the author’s collaborators can potentially be harmed by a colleague’s misconduct. Research has shown that in such situations, the citations of prior collaborators can fall by 8–9%.10 There can be additional harm to personal relationships amid and across teams as well, and unhappiness can negatively impact productivity.11
Preventing substandard research
Research normally occurs at the speed of a marathon, but during a pandemic, the pace is more like a sprint.1 The prior slower pace gave space for reflection on quality, as well as time for researchers to rest their minds and bodies. During the pandemic there is the potential for the race of research to occur with fewer reflective and rest periods. Less reflection can facilitate missed opportunities for quality checks such as robust reviews of study applications by research ethics committees (RECs) and quality checks by researchers and their supervisors. Less rest can facilitate fatigue and mistakes of human error or judgement (eg, taking short cuts rather than performing standard practice).12 During a pandemic, research teams should build in time for reflection such as scheduled spot-checking of data.13 Rejuvenation time can also be scheduled such as a team exercise break for a brisk walk around the campus (respecting social distancing) or even a fun musical tune blasted across the public announcement system signalling a 3 min brain break.
RECs cannot be expected to routinely have membership of immunologists, microbiologists and pulmonologists, for example, yet these are key topic experts for research protocols dealing with COVID-19. In an effort to provide high-quality reviews of these protocols, RECs should create a list of go-to experts who can be retained as consultants for these reviews. These experts can be readily found through a search of PubMed or international scientific professional societies. Some universities also provide experts collated by topic on their websites. It is not enough to have a fast-track review process that speeds the protocol submissions through the REC; a robust review process that reflects on both science and ethics is needed. Considering that many COVID-19 projects involve epidemiology and contact tracing, reviewers should also pay special attention to the privacy protection of human participants.
Research ethics and integrity training should be mandatory for all researchers so that they have a foundational understanding of both good research practice, ethical sensitivities, types of research misconduct and substandard practice, as well as the consequences of the latter. These courses are essential to fostering a research culture that embraces both ethics and quality, and they can potentially deter research misconduct and help researchers feel prepared to manage dilemmas pertaining to research ethics and research integrity.14 15 Many of these courses are offered online.
Researchers should have ready access to services which can provide timely, expert advice to research dilemmas involving topics such as authorship disputes, image manipulation, citations and referencing, informed consent, participant recruitment, and so on. These services could include an online FAQ, an ethics consult service or video tutorials. Another option is on-site research coaches who are an adjunct to the research supervisor, available for quick advice.16 ‘Publish or perish’ is a harmful mindset and the pandemic’s ‘need for speed’ needs calibration which can be aided by coaching, supervision and mentoring that recognises the humanness of the research process. Researchers need advice, support, rest and tools.17
Robust peer review of manuscripts is vital, especially when open access publishing makes them easy to find and view in full text. The pandemic has created a surge of manuscripts, yet the fleet of journal peer reviewers is a voluntary service to the research community in the setting of concurrent commitments which often include employment and family. The research topics are often complex and highly specialised and thus the peer review assignment must be thoughtful, and include avoiding conflict of interest (eg, research competitor, sponsor funding). Journals must also mitigate time when manuscripts age with long peer review times when reviewers cannot be secured. Rapid review should not compromise the quality of the review, but rather the efficiency of the process should be improved by identifying bottlenecks, removing steps that do not add value, and increasing staff and tools for the administrative/document handling tasks.18 19
When research integrity problems are found, they should be dealt with in a professional manner that includes whistle-blower protection. Confirmed infractions of policies and standards20 should have meaningful consequences that reflect on root cause in order to deter repeat offences. Also, by publishing the results of investigations, these can be used for training purposes, and routine trending for areas of organisational concern can be identified (eg, supervision issues). It is also important to announce when investigations do not confirm misconduct or research quality issues so that accused personnel can be vindicated. There may be regional regulations that restrict the personal details of publishing integrity investigations (eg, European Union General Data Protection Regulation); however, there is value to the publishing of anonymised case summaries for both institutional transparency and training purposes. National research integrity offices can be sources of investigation summaries, training and consultation for researchers of all levels, and their continued support and funding is vital to fostering ethical and robust research.
Contributors Bramstedt KA is the sole author.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests The author owns a private consulting company focused on bioethics and clinical ethics (AskTheEthicist, LLC).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon request.
↵Search terms COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, 2019-nCoV, 2019 novel coronavirus, Wuhan coronavirus
↵Retraction Watch (https://retractionwatch.com/retracted-coronavirus-covid-19-papers) was used as the source of these articles as they catalogue articles from numerous journal indexing databases beyond MEDLINE, as well as preprint servers. The source also mentioned one COVID-19-related conference paper that was withdrawn before presentation with unclear explanation.